Significant Ownership of Laurion Capital Management LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Laurion Capital Management LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- Jason Riesel - Jason Riesel. General Counsel & CCO
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
CIK context first
Continue from Laurion Capital Management LP
Significant Ownership of Laurion Capital Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | Common Stock, par value $0.001 per share | 7.7% | $9,880,747 | 4,796,479 | Laurion Capital Management LP | 31 Dec 2025 | ||
| IMUX | IMMUNIC, INC. | Common Stock, $0.0001 par value | 6.1% | $12,290,661 | 839,526 | Laurion Capital Management LP | 30 Jun 2026 | ||
| RLYB | Rallybio Corp | Common Stock, par value $0.0001 per share | 5.7% | $175,598 | 302,756 | Laurion Capital Management LP | 31 Mar 2026 | ||
| RLYB | Rallybio Corp | Common Stock, par value $0.0001 per share | 0% | $0 | 0 | Laurion Capital Management LP | 30 Jun 2026 |
Schedules 13D/G Reported by Laurion Capital Management LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.